Loading organizations...
§ Private Profile · P.O.B. 337, Carmel building, Yokneam 2069205, ISRAEL
Rapid Medical is a company.
Rapid Medical has raised $79.0M across 3 funding rounds.
Key people at Rapid Medical.
Rapid Medical was founded in 2008 by Shimon Eckhouse (Co founder and chairman).
Rapid Medical has raised $79.0M in total across 3 funding rounds.
Rapid Medical develops advanced neurovascular therapy solutions, providing responsive and remotely adjustable interventional tools specifically designed for treating ischemic and hemorrhagic stroke. The company leverages proprietary manufacturing techniques to create devices that offer precise control, enabling physicians to tailor procedures to individual patient anatomies and diverse clinical presentations. Their product portfolio addresses the critical need for adaptable technology in complex neurovascular interventions.
The company was co-founded in 2008 by Ronen Eckhouse and Dr. Shimon Eckhouse, who also serves as chairman of the board. Their insight stemmed from the understanding that traditional stroke therapies often lacked the flexibility required to effectively address the unique anatomical variations and diverse nature of each stroke. This led to the development of tools engineered to adapt in real-time, aiming to overcome the limitations of conventional, one-size-fits-all approaches.
Physicians utilizing interventional neurovascular techniques are the primary customers for Rapid Medical's products. The company’s vision is to pioneer solutions that expand the possibilities within neurovascular therapy, ultimately striving for optimized stroke procedures and improved outcomes for patients worldwide. They aim to continuously advance stroke intervention by providing innovative, patient-specific tools that empower medical professionals.
Key people at Rapid Medical.
Rapid Medical was founded in 2008 by Shimon Eckhouse (Co founder and chairman).
Rapid Medical has raised $79.0M in total across 3 funding rounds.
Rapid Medical's investors include MicroPort, Chen Chen, Deep Insight, John McCallum, Bruce Wang, Agate Medical Investments, RocSon Medtech Fund, Alon Maor, Liefeng Qu, Gefen Capital, Winnovation.
Rapid Medical has raised $79.0M across 3 funding rounds. Most recently, it raised $50.0M Series D in May 2021.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| May 25, 2021 | $50M Series D | Microport | Chen Chen, Deep Insight | Announced |
| Apr 23, 2019 | $20M Series C | John Mccallum, Bruce Wang | Agate Medical Investments, Rocson Medtech Fund | Announced |
| Jul 17, 2017 | $9M Series B | Alon Maor, Liefeng QU | Gefen Capital, Winnovation | Announced |
Rapid Medical is a medtech company headquartered in Yokneam, Northern Israel, specializing in neurovascular devices for stroke treatment.[1][2] It develops responsive, remotely adjustable interventional tools using proprietary manufacturing techniques to address ischemic and hemorrhagic strokes, serving physicians and patients by enabling real-time adaptation to individual anatomies for safer, more precise procedures.[1][2] The company has treated over 40,000 patients, holds 100+ issued patents, and boasts 75+ clinical publications, with recent milestones including FDA clearance in the US, MDR approval in Europe, and over 1,000 cases with its DRIVEWIRE™ 24 device in North America.[2]
(Note: Search results also reference a separate US-based logistics firm named Rapid Medical focused on medical delivery services, but the primary context and official site align with the Israeli neurovascular medtech company.)[4]
Rapid Medical emerged from Israel's robust medtech ecosystem, establishing its headquarters in Yokneam with global offices including Southlake, Texas.[1] While exact founding details are not specified in available data, the company's leadership team—featuring executives like Ronen Eckhouse, Michal Shriki, Dr. Walid Haddad, Eitan Havis, James Romero, and Giora Kornblau—brings decades of global MedTech experience to advance neurovascular innovations.[1] Pivotal early traction includes FDA clearance for its active access solutions, enabling initial US neurovascular cases, and pioneering the world's first robotic thrombectomy device for ischemic stroke procedures.[2] Recent appointments, such as industry veteran Nir Nimrodi to the board, underscore its evolution toward broader market expansion.[2]
Rapid Medical stands out in stroke intervention through active technology that adapts to patient-specific anatomies, unlike static conventional tools that risk compromising safety.[1][2]
Rapid Medical rides the wave of personalized neurovascular therapy, addressing the variability of strokes—where no two are alike—amid rising demand for minimally invasive interventions.[1][2] Timing is critical as stroke incidence grows with aging populations and improved acute care survival rates, while market forces favor adaptive devices over one-size-fits-all options that limit safety and efficacy.[2] By influencing the ecosystem through innovations like robotic thrombectomy and active access platforms, it pushes boundaries in interventional neurology, fostering clinical publications and patents that set standards for future medtech.[2] Its Israel-US footprint leverages global R&D hubs, amplifying impact in a sector ripe for disruption via precision engineering.[1][3]
Rapid Medical is poised for accelerated global adoption, building on US and European approvals to expand active technology platforms like DRIVEWIRE into more procedures and regions.[2] Trends in AI-assisted robotics, personalized medicine, and value-based care will shape its trajectory, potentially integrating further with endovascular systems for even broader stroke management.[2] Its influence may evolve from niche innovator to ecosystem leader, driving better patient outcomes as medtech converges with robotics—expanding what's possible, as its mission states, right from its Israeli roots.[1]
